Our work aligns with the recommendations of the International Ki67 Breast Cancer Working Group (IKWG) regarding Ki67 IHC being accepted to decide chemotherapy for the patient if it has a value of 30% or more after maintaining training modules for pathologists together with adopting good staining and scoring protocols [43]. This evidence concerns the gene MKI67 and breast carcinoma.